EMD Millipore Gains Exclusive Rights to Singulex Technology

EMD Millipore announced Thursday that it has entered into a definitive agreement with Singulex to obtain the exclusive rights to the company’s single molecule counting technology. EMD Millipore will pay Singulex money upfront, royalties and make additional payments if certain sales-based milestones are met.

SMC technology combines single enhancement and background reduction techniques to provide ultra-sensitive protein detection in immunological assays, making it a more attractive option than the current standard of care, EMD Millipore says.

Previous assays have been able to detect an estimated 5 percent of proteins in the proteome because of a low amount of biomarkers, leaving the majority of proteins undetected.

Based in Billerica, Mass., EMD Millipore is a subsidiary of Merck KGaA and has operations in 66 countries.

Singulex develops immunoassay products and provides laboratory testing services. It is based in Alameda, Calif. — Jason Scott